CSIMarket
 
Acumen Pharmaceuticals Inc   (ABOS)
Other Ticker:  
 
 
Price: $4.1800 $0.09 2.200%
Day's High: $4.24 Week Perf: -2.34 %
Day's Low: $ 4.01 30 Day Perf: 32.7 %
Volume (M): 204 52 Wk High: $ 11.31
Volume (M$): $ 853 52 Wk Avg: $4.42
Open: $4.04 52 Wk Low: $1.81



 Market Capitalization (Millions $) 227
 Shares Outstanding (Millions) 54
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 0

Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc is a biotechnology company focused on the development of therapeutics for neurodegenerative diseases. It was founded in 2008 and is headquartered in South San Francisco, California.

The company's main focus is on Alzheimer's disease and related neurological disorders. Acumen Pharmaceuticals aims to identify and develop innovative drugs that target the underlying causes of these diseases. Their research is centered on the discovery of small molecules that can effectively inhibit the accumulation and spread of pathological proteins in the brain, which are believed to be major contributors to neurodegeneration.

Acumen Pharmaceuticals utilizes advanced technologies and collaborations with leading academic institutions to support their drug discovery and development efforts. They aim to deliver disease-modifying treatments that can slow or halt the progression of neurodegenerative diseases like Alzheimer's, thereby improving the quality of life for affected individuals.

Overall, Acumen Pharmaceuticals Inc strives to make meaningful advancements in the field of neurodegenerative disease therapeutics through their innovative research and development initiatives.


   Company Address: 427 Park St. Charlottesville 22902 VA
   Company Phone Number: 297-1000   Stock Exchange / Ticker: NASDAQ ABOS
   ABOS is expected to report next financial results on March 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Unleashing the Potential of Sabirnetug: A Ray of Hope for Alzheimer's Disease Treatment

Published Wed, Feb 21 2024 1:00 PM UTC

Exploring the Efficacy of Sabirnetug (ACU193) in Early Alzheimer's Disease: Insights from Phase 1 INTERCEPT-AD StudyAlzheimer's disease (AD) is a devastating neurodegenerative disorder affecting millions of individuals worldwide. Despite extensive research, there is currently no cure for AD, and available treatments only provide temporary symptomatic relief. Therefore, there...

Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc Suffers Operating Deficit in Q3 2023, Seeks Strategies for Recovery



The recent earnings report of Acumen Pharmaceuticals Inc (NASDAQ: ABOS) for the financial period ending September 30, 2023, has sparked concerns within the market. The clinical-stage biopharmaceutical company, focused on developing a therapeutic solution for Alzheimer's disease, revealed an alarming operating deficit of $-16.039 million. This represents a significant deterioration from the previous year's third quarter deficit of $-11.371 million. Coupled with the stock's recent decline and various market indicators, it appears that Acumen Pharmaceuticals Inc is facing significant challenges and market headwinds.
Operating Deficit Growth:
One of the most concerning factors highlighted in Acumen Pharmaceuticals' recent earnings report is the substantial growth in their operating deficit. The company experienced a significant shortfall of $-12.957 million in the third quarter of 2023, compared to $-10.710 million in the same period the previous year. This worrying trend suggests that the company's financial situation is deteriorating, raising questions about their ability to sustain operations and deliver on their promising therapeutic pipeline.

Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc, a Rising Player in the Biotech & Pharmaceuticals Industry, Faces Continued Challenges with a Net Loss of $-11.610 Million in Q2 2023

Financial News Report: Overlooked Biotech & Pharmaceuticals Companies and Acumen Pharmaceuticals Inc's Strong Performance
In the world of Biotechnology & Pharmaceuticals, attention is often focused on the large companies dominating the industry. However, a few smaller corporations are emerging with noteworthy earnings and potential for growth. One such company is ABOS, which recently announced an operating loss of $-13.478 million for the second quarter of 2023. This represents a deterioration from the operating loss of $-10.411 million reported in the same quarter of the previous year.
Investors are speculating on whether ABOS will begin to report positive top-line results, which will be a major determinant of its financial performance. Unfortunately, the financial time-frame closing on June 30, 2023, revealed a net loss of $-11.610 million, a significant increase from the $-10.151 million reported in the corresponding quarter a year ago. This suggests that despite some improvements, ABOS is still facing challenges in its profitability.

Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc. Faces Operating Deficit in Q1 2023 Amidst Rapid Growth

Biotechnology & Pharmaceuticals Sector Sees Operating Deficit for Q1 2023
Investors in the biotechnology and pharmaceuticals sector may be interested to learn that researchers are beginning to interpret the first quarter of 2023 results. According to recent reports, the ABOS has announced an operating deficit of $-13.135 million for the January to March 31 2023 reporting season. This is due to the fact that the rising entity has not yet reported any revenue.
However, when compared to the first quarter of 2022, where the ABOS announced an operating deficit of $-9.206 million, this result is not entirely surprising. The organization has also seen a net loss of $-11.307 million, which has expanded from $-9.129 million over the same three months a year ago.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com